https://www.idblanter.com/search/label/Template
https://www.idblanter.com
BLANTERORBITv101

Tocilizumab Uspi / 1.3 polyarticular juvenile idiopathic arthritis (pjia) actemra® (tocilizumab) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.

Friday, January 8, 2021